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BACKGROUND: Breast cancer (BC) therapies can have negative effects on bone. Current guidelines recommend antiresorptive therapy
based on bone mineral density (BMD), and emerging guidelines include both clinical risk factors and BMD to assess the overall
fracture risk. A retrospective, case–controlled study based on current and emerging guidelines was conducted in women with newly
diagnosed BC to identify those who were at increased fracture risk based on current and emerging guidelines.
METHODS: Baseline characteristics, fracture risk factors, and lumbar–spine (LS) and total-hip BMD in women with BC (88 premeno-
pausal and 402 postmenopausal) were assessed to determine who would receive bisphosphonate therapy based on current and
emerging guidelines.
RESULTS: Among patients with estrogen-receptor-positive (ER
þ) BC, 18.8% of premenopausal and 36.9% of postmenopausal women
were osteopenic at LS. In the postmenopausal cohort, osteoporosis was more prevalent in patients with ER
þ vs ER
– BC. Current
guidelines identified 8.9% of patients as eligible for antiresorptive therapy, clinical risk factors alone identified 6.5%, and BMD plus
clinical risk factors identified 28.6%.
CONCLUSIONS: In addition to fracture risk factors present at BC diagnosis, cancer therapies leading to BMD loss further increase
fracture risk. Evaluating both BMD and clinical risk factors may allow more effective identification of BC patients with elevated fracture
risk.
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Breast cancer (BC) is the most prevalent malignancy in women
worldwide, with an estimated global incidence of more than 1.3
million new cases and nearly 465000 deaths in 2007 (Garcia et al,
2007). Improvements in detection of breast tumours over the last
few decades have resulted in the early diagnosis of the majority of
BCs, thus allowing more effective therapy (American Cancer
Society, 2007). Expression of estrogen receptors (ERs) and/or
progesterone receptors in tumour cells is a major determinant of
systemic therapy – hormone-receptor (HR)-negative BCs are
typically treated using cytotoxic chemotherapy, whereas endocrine
therapy is the adjuvant therapy of choice for HR
þ tumours
(Anderson et al, 2002; Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG), 2005). However, both endocrine and cytotoxic
therapies have known negative effects on bone health (Pfeilschifter
and Diel, 2000).
Estrogen has a key role in preserving bone health in both
premenopausal and postmenopausal women. After menopause,
estrogen depletion is associated with increased rates of bone
turnover, decreased bone mineral density (BMD), and altered
microarchitecture in trabecular bone, leading to increased risk of
fragility fractures (Wehrli et al, 2008). In addition to natural bone
loss associated with ageing, therapies for BC can impair bone
health directly, or indirectly by disrupting estrogen production
and signalling (Pfeilschifter and Diel, 2000). For example, ovarian
suppression using agents such as goserelin in premenopausal
women, or aromatase inhibitor (AI) therapy in postmenopausal
women, can result in substantial bone loss (Eastell et al, 2008;
Gnant et al, 2008). Adjuvant AI therapy is now the standard of care
for postmenopausal women with HR
þ BC because of its superior
disease-free survival results and more favourable side-effect profile
(particularly with regard to venous thrombosis and endometrial
cancers) compared with tamoxifen (Howell et al, 2005; Thurlimann
et al, 2005; Coombes et al, 2007). However, AIs vary in their ability
to suppress estrogen levels in vivo (Geisler et al, 2008), and recent
clinical trial data indicate that the near-complete estrogen
suppression associated with letrozole treatment may further
improve overall survival vs tamoxifen in postmenopausal women
with HR
þ BC (Mouridsen et al, 2009). Overall, the profound
estrogen depletion achieved with AI therapy is associated with
decreased BMD and increased fracture risk (Coombes et al, 2004;
Howell et al, 2005; Thurlimann et al, 2005; Eastell et al, 2008).
Cytotoxic chemotherapy can also impair bone health either
directly, through effects on bone (e.g., methotrexate), or indirectly,
through premature ovarian failure (Pfeilschifter and Diel, 2000;
Shapiro et al, 2001). Overall, both natural and cancer treatment-
induced bone loss (CTIBL) can increase fracture risk in women
with BC.
Received 29 September 2009; revised 11 December 2009; accepted 18
December 2009; published online 19 January 2010
*Correspondence: Dr P Hadji;
E-mail: hadji@med.uni-marburg.de
British Journal of Cancer (2010) 102, 645–650
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sFortunately, several studies demonstrated the efficacy of
antiresorptive agents such as bisphosphonates for preventing
BMD loss and reducing fracture risk associated with BC therapy
(Gnant et al, 2008; Lester et al, 2008; Brufsky et al, 2009). For
example, in the ABCSG-12 study (N¼1803) in premenopausal
women receiving ovarian suppression plus endocrine therapy for
early stage BC, patients receiving concomitant zoledronic acid
(4mg every 6 months) for 3 years maintained BMD during the
treatment period compared with a significant BMD loss in patients
who did not receive bisphosphonates ( 11.3% at lumbar–spine
(LS),  7.3% at hip; Po0.0001 for both) (Gnant et al, 2008). Two
years after therapy cessation, patients who had received zoledronic
acid experienced increases in BMD (þ4.0% at LS, P¼0.022;
þ3.9% at hip, P¼0.073), but BMD remained below baseline levels
in the patients who did not receive zoledronic acid ( 6.3% at LS,
P¼0.001;  4.1% at hip, P¼0.058) (Gnant et al, 2008). In the
Z-FAST study (N¼602) at 36 months, postmenopausal women
receiving zoledronic acid (4mg every 6 months) at the start of
adjuvant AI therapy had significant increases in BMD (þ3.7 at LS,
þ1.7% at hip; Po0.0001 for both) compared with significant
BMD losses ( 3.0% at LS,  3.6% at hip; Po0.0001 for both) in
patients for whom zoledronic acid initiation was delayed (Brufsky
et al, 2009). In the ARIBON study (N¼131), postmenopausal
women receiving AI therapy plus ibandronate (150mg monthly)
experienced significant increases in BMD compared with placebo
(þ3.0% vs  3.2% at LS, P¼0.002; þ0.6% vs  3.9% at hip,
P¼0.003) (Lester et al, 2008). To date, there has not been a direct
comparison of bisphosphonate BMD effects in the BC setting.
Established society guidelines for managing bone health in
women with BC recommend the use of BMD measurements to
identify candidates for preventive bisphosphonate therapy, with
additional risk factors used only to identify high-risk patients who
require close follow-up with dual-energy X-ray absorptiometry
(DXA) (Hillner et al, 2003). This essentially limits bone-protective
therapy to patients with DXA confirmation of osteoporosis (i.e.,
T-score p 2.5). Unfortunately, DXA scanning of all patients
might not be feasible in some settings. However, additional factors,
including family and personal history of fragility fractures, age,
long-term medications such as corticosteroids, low body mass
index (BMI), and smoking, have all been associated with an
increased fracture risk that is independent of BMD (Cummings
et al, 1995; Kanis et al, 2005, 2007; Siris et al, 2006). To place BMD
and other risk factors in the context of identifying women with BC
who are at increased risk of fracture and are likely to benefit most
from bisphosphonate therapy, a panel of experts recently evaluated
data from large clinical trials in postmenopausal women and
women with BC to develop international guidelines for using
clinical risk factors for fracture along with BMD measurements
(when available) (Hadji et al, 2008). To date, these emerging
international guidelines have not been validated for fracture
prevention in a prospective trial. Therefore, the purposes of the
present single-institution study are two-fold: first, to evaluate the
baseline BMD status of premenopausal and postmenopausal
women with BC and the prevalence of baseline fracture risk
factors in postmenopausal women with BC; second, to use these
baseline data to compare current society guidelines with the non-
BMD-dependent guidance for fracture risk assessment in post-
menopausal patients with BC.
MATERIALS AND METHODS
Patients
Premenopausal and postmenopausal women with BC and healthy
women without BC (control group) were identified from patients
treated at the gynaecological department of the Philipps-University
of Marburg between 2003 and 2006. Premenopausal patients
were defined as those having current menses, or estradiol levels
greater than 20pgml
 1 and follicle-stimulating hormone levels
o15pgml
 1. The two groups (N¼1184) were matched according
to the following criteria: age (±9 years), weight (±16kg), height
(±13cm), BMI (±3kgm
 2), hormone replacement therapy
(HRT) use (1:1), and smoking (1:1). The final analysis included
88 pairs of patients and controls in the premenopausal cohort and
402 pairs in the postmenopausal cohort. All women completed a
detailed questionnaire that identified all relevant risk factors for
osteoporosis. The study was conducted in accordance with the
Declaration of Helsinki and in accordance with the local ethical
committee of the Philipps-University of Marburg.
BMD assessment
Bone mineral density was measured by the same operator by DXA
with a Lunar Prodigy densitometer (GE/Lunar Healthcare Cor-
poration, Madison, WI, USA) using a standard protocol for the
femoral neck (FN), total hip (TH), and LS. The mean interval
between BC diagnosis and baseline BMD assessment was
approximately 15 days for both premenopausal and postmeno-
pausal patients.
Guideline comparison and estimation of fracture
prevention
Recommendations for managing bone health in women with BC
were obtained from the American Society of Clinical Oncology
(ASCO) guidelines (Hillner et al, 2003), and the emerging
international guidelines were obtained from an expert panel of
oncologists and endocrinologists (Hadji et al, 2008). Baseline data
from postmenopausal women with BC included in this chart
review were assessed according to the ASCO and emerging
international guidelines to determine which patients would be
eligible to receive bisphosphonate therapy. Fracture prevention
was estimated based on fracture data recorded in the National
Osteoporosis Risk Assessment (NORA) study in postmenopausal
women (Siris et al, 2004) using the treatment criteria outlined in
the ASCO guidelines (T-score p 2.5) (Hillner et al, 2003), and the
emerging international guidelines (T-score o 2.0 or at least two
risk factors including T-score o 1.5, age 465 years, low BMI
(o20kgm
 2), family history of hip fracture, personal history of
fragility fracture after 50 years of age, oral corticosteroid use 46
months, and smoking) (Hadji et al, 2008). For this estimation, it
was assumed that patients who would have received therapy
according to either of the evaluation criteria would be protected
from fracture. Although this is a crude estimate, it may
approximate the relative protection afforded by the ASCO and
emerging international guidelines, but does not consider the
relative efficacy of bisphosphonate therapy.
Statistical analyses
Data analysis was carried out using SPSS version 12.0 to test
differences in the mean values between groups using the t-test for
parametric, the U-test for nonparametric, and the w
2 test for
categoric variables.
RESULTS
Baseline patient characteristics
Among 88 pairs of premenopausal women (88 with BC and 88
controls) and 402 pairs of postmenopausal women (402 with BC
and 402 controls), baseline characteristics were well balanced
(Table 1). Overall, 5.8% of premenopausal women and 41.7% of
postmenopausal women had received previous HRT. No women in
the control group were receiving cancer therapies, whereas BC
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spatients were undergoing standard chemotherapy or endocrine
therapies that suppressed estrogen levels (i.e., tamoxifen or an AI,
such as anastrozole, letrozole, or exemestane). Endocrine treatment
was recorded for 79.4% of premenopausal (tamoxifen) and 91.6%
of postmenopausal patients (tamoxifen or AI). Stratification by ER
status revealed ER
þ BC in 74 and 80% of the premenopausal and
postmenopausal women, respectively.
Prevalence of osteopenia, osteoporosis, and fracture risk
factors
Among women in the control groups, the prevalence of low BMD
(osteopenia or osteoporosis) was substantially higher in the
postmenopausal group (X43%) compared with the premenopausal
group (p25%) at all sites (FN, TH, and LS). All BC patients
underwent BMD measurement shortly after diagnosis. The mean
time between diagnosis and BMD measurement was 14.5 days for
premenopausal and 14.8 days for postmenopausal women. Similar
to patients in the control groups, the prevalence of low BMD
among patients with BC was higher among postmenopausal
compared with premenopausal groups. Measurements of BMD at
LS (Figure 1A) and TH (Figure 1B) in patients with ER
þ BC
revealed normal BMD in more premenopausal patients compared
with postmenopausal patients (480 vs B60%). A similar BMD
pattern was seen in women with ER
– tumours (data not shown).
The overall incidence of osteopenia was 17% in premenopausal
and 36% in postmenopausal patients with ER
þ BC, whereas the
corresponding osteoporosis rates were 1 and 6%, respectively.
Stratification of patients by ER status revealed higher prevalence of
LS osteopenia in premenopausal patients with ER
– vs ER
þ BC
(18.2 vs 15.4%; Figure 2A), whereas LS osteopenia was more
prevalent in postmenopausal patients with ER
þ vs ER
– BC (35.9 vs
22.4%, respectively; Figure 2B). Moreover, LS osteoporosis was
also more prevalent in postmenopausal patients with ER
þ vs ER
–
BC (3.1 vs 1.3%; Figure 2B). The prevalence of clinical factors
associated with increased fracture risk independent of BMD is
presented in Table 2 (Cummings et al, 1995; Kanis et al, 2005,
2007; Siris et al, 2006; Hadji et al, 2008). Except for age (465
years), history of smoking (B28%), and AI therapy (B30%), each
validated fracture risk factor had low prevalence (o6%) among
postmenopausal patients with ER
þ BC; however, 44.4% of these
patients had T-scores o 1.5.
Assessment of the need for treatment and fracture risk
using current and emerging international guidelines
Current guidelines from ASCO recommend BMD screening for all
women receiving AI therapy and antiresorptive agents for women
with T-scores p 2.5 (Hillner et al, 2003). Applying ASCO
guidelines to the ER
þ patient population in this study (i.e., the
patients most likely to receive AIs), 8.9% of the postmenopausal
patients would be eligible for bisphosphonate therapy (Figure 3A)
(Siris et al, 2004). In contrast, applying the criteria from emerging
Table 1 Baseline characteristics of matched patient groups
Premenopausal Postmenopausal
Characteristics Healthy (n¼88) BC (n¼88) Healthy (n¼402) BC (n¼402)
Age (years)±s.d. 41.4±6.5 42.0±6.2 62.2±8.3 61.5±10.2
Mean body mass index (kgm
 2)±s.d. 23.7±4.0 23.9±3.9 26.9±4.4 26.9±4.6
HRT (%) 5.8 5.8 41.7 41.7
Smoking (%) 48.8 48.8 28.3 28.3
Menopausal status
Mean time since becoming postmenopausal (years)±s.d. — — 15.2±9.4 14.6±10.3
Mean BMD T-score
TH –0.11 –0.07 –0.68 –0.48
LS 0.26 0.03 –0.85 –0.57
Endocrine treatment
a (%)
Tamoxifen — 79.4 — 62.0
AI — — — 29.6
Mean time from BC diagnosis to BMD (days) — 14.5 — 14.8
Abbreviations: AI¼aromatase inhibitor; BC¼breast cancer; BMD¼bone mineral density; HRT¼hormone replacement therapy; LS¼lumbar–spine; s.d.¼standard deviation;
TH¼total-hip.
aPatients not identified as receiving endocrine treatment had hormone-receptor-negative breast cancer.
81.3
Normal, T-score   –1
Osteopenic, T-score –1 to –2.5
Osteoporotic, T-score   –2.5
Normal, T-score   –1
Osteopenic, T-score –1 to –2.5
Osteoporotic, T-score   –2.5
18.8
83.1
15.4
1.5
60.9
35.9
3.1
0
54.2
36.9
8.9
Postmenopausal women Premenopausal women
Postmenopausal women Premenopausal women
P
a
t
i
e
n
t
s
,
 
%
100
90
80
70
60
50
40
30
20
10
0
P
a
t
i
e
n
t
s
,
 
%
100
90
80
70
60
50
40
30
20
10
0
Figure 1 Prevalence of osteopenia and osteoporosis at (A) lumbar–
spine and (B) total-hip in women with estrogen-receptor (ER)-positive
breast cancer.
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sinternational guidelines for managing AI-associated bone loss
(AIBL; i.e., T-score o  2.0 and X2 clinical risk factors including
T-score o 1.5) (Hadji et al, 2008) identified more women who
should receive antiresorptive therapy. Although clinical risk
factors alone (i.e., not including T-score) identified 6.5% of
postmenopausal patients with ER
þ BC in this study as eligible for
bisphosphonate treatment, 25.5% of these patients would be
eligible for treatment using T-score o 2.0 as the sole criterion.
However, selecting patients with two or more clinical risk factors
(including T-score o 1.5) identified a somewhat larger propor-
tion of patients (28.6%) who would be eligible for treatment
(Figure 3A) (Siris et al, 2004). Based on NORA fracture incidence
data from 170083 women (Siris et al, 2006), limiting bispho-
sphonate treatment according to current ASCO guidelines is
estimated to prevent only 18% of potential fractures, whereas
treatment based on emerging international guidelines would
prevent approximately 45% of potential fractures (Figure 3B)
(Siris et al, 2004).
DISCUSSION
Decreased BMD and increased fracture risk are well-documented
adverse events associated with BC therapies (Pfeilschifter and Diel,
2000; Hadji, 2009). Bisphosphonates have an established role in
treating postmenopausal osteoporosis and have demonstrated
clinical benefits for preventing bone loss during therapy for BC
(Coleman, 2008; Hadji, 2009). The largest body of evidence to date
is for twice-yearly intravenous zoledronic acid (4mg), which can
prevent bone loss and improve BMD in premenopausal and
postmenopausal women receiving adjuvant endocrine therapy for
BC (total N¼2598) (Schenk et al, 2007; Brufsky et al, 2008; Gnant
et al, 2008).
In Europe, current Arbeitsgemeinschaft Gyna ¨kologische Onko-
logie e.V. (AGO) guidelines (www.ago-online.de) support the use
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Figure 2 Prevalence of osteopenia and osteoporosis at the lumbar–
spine in (A) premenopausal and (B) postmenopausal women with breast
cancer, by estrogen-receptor (ER) status.
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Figure 3 (A) Proportion of patients eligible for antiresorptive therapy
and (B) estimation of the percentage of fractures prevented based on
fracture-risk assessment using current (American Society of Clinical
Oncology (ASCO)) and emerging international guidelines. Estimates based
on fractures recorded in the National Osteoporosis Risk Assessment
(NORA) study (Siris et al, 2004).
Table 2 Clinical risk factors for fracture and their prevalence in
postmenopausal women with estrogen-receptor-positive (ER
+) breast
cancer
Patients
Risk factors Evaluable, n
Risk-factor-
positive,
n (%)
Validated
a
T-score o–1.5 322 143 (44.4)
Age 465 years 322 131 (40.7)
Low BMI (o20kgm
 2) 322 10 (3.1)
Family history of hip fracture 322 9 (2.8)
Personal history of fragility fracture after
age 50 years
322 18 (5.6)
Oral corticosteroid use 46 months 322 2 (0.6)
Smoking 378 107 (28.3)
AI therapy 284 84 (29.6)
Possible
b
Chemotherapy 402 148 (36.8)
Abbreviations: AI¼aromatase inhibitor; BMI¼body mass index; ER¼estrogen
receptor.
aValidated in large clinical trials of healthy postmenopausal women (except
AI therapy) (Cummings et al, 1995; Kanis et al, 2005, 2007; Siris et al, 2006; Hadji et al,
2008).
bCould not be validated because of insufficient trial data.
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sof bisphosphonates to prevent and treat bone loss during adjuvant
therapy for BC but do not specify a threshold for intervention,
whereas the St. Gallen Expert Consensus does not recommend
routine bisphosphonate use in women receiving AIs who have
normal bone health (Goldhirsch et al, 2009). Current ASCO
guidelines depend on osteoporotic BMD T-scores to identify
patients with early BC who are eligible for bone-targeted therapy
(Hillner et al, 2003). However, the majority of fractures occur in
women who are osteopenic (BMD –1.0 to –2.5) (Siris et al, 2004),
and treatment based on current guidelines will not prevent
fractures in these women. Recent emerging international guide-
lines for bone health management in postmenopausal women
receiving AI therapy for BC has now expanded the treatment
criteria to include clinical risk factors in addition to BMD to guide
therapy (Hadji et al, 2008).
The purpose of our study was to assess baseline characteristics
in women with newly diagnosed BC and determine the proportion
of patients who would receive bisphosphonate therapy based on
ASCO and emerging international guidelines (Hillner et al, 2003;
Hadji et al, 2008). In addition, because fracture data were
unavailable for our patients, we estimated the proportion of
patients in each group who would experience a fracture by
comparing baseline data in our patients with fracture data from
the NORA study. Results from our study indicate that the emerging
international guidelines (BMD þ clinical risk factors) may
identify more patients likely to benefit from bisphosphonate
therapy. Initiating bisphosphonate treatment according to emer-
ging international guidelines is predicted to prevent 45% of
potential fractures in postmenopausal patients vs 18% for
treatment initiated per ASCO guidelines (Figure 3B) (Siris et al,
2004). These estimates are based on data from the NORA study
showing that although 33% of fractures occurred in women with
T-scores p 2.0, only 18% occurred in women with osteoporotic
BMD values (T-score p 2.5), indicating that a large proportion of
patients experience a fracture before developing osteoporosis (Siris
et al, 2004). Additional data from the NORA study indicate that at
least 45% of fractures occur in women with two or more fracture
risk factors. It is important to note that our estimates of fracture
prevention are based on fracture risk in healthy women (Siris et al,
2006) and might therefore underestimate the true protective effect
of bisphosphonates in the BC setting.
Results from our study indicate that both premenopausal and
postmenopausal women with BC may already have low BMD or
develop this condition soon after BC diagnosis. Furthermore,
because BMD measurement occurred within a short time from BC
diagnosis (B15 days) in this study, bone loss that would occur
during BC treatment is not considered. For example, AIBL and
ovarian suppression-associated bone loss are most severe within
the first 3 years of beginning therapy, but remain elevated for the
duration of therapy (Howell et al, 2005; Thurlimann et al, 2005;
Coombes et al, 2007; Eastell et al, 2008; Gnant et al, 2008).
Therefore, patients are likely to experience additional decreases in
BMD during BC treatment, making the management of bone health
an increasing concern. This is especially true for postmenopausal
patients with ER
þ BC, in whom osteopenia and osteoporosis were
more prevalent at baseline. Approximately 30% (n¼84) of
postmenopausal women with ER
þ BC were scheduled to receive
AI treatment, which might further exacerbate bone loss in this
group over time.
Recently, the FRAX Web-based tool (www.shef.ac.uk/FRAX/
index.htm) was developed by the World Health Organization to
evaluate fracture risk in healthy women based on individual patient
models integrating clinical risk factors and FN BMD. These data are
used to calculate the 10-year probability of hip fracture or any major
osteoporotic fracture (forearm, hip, shoulder, or clinically overt in
spine), with or without BMD measurements. However, because the
FRAX tool does not permit including cancer therapy-associated bone
loss as a variable in the fracture risk assessment, it will probably
underestimate the absolute fracture risk for women with BC.
Therefore, risk assessment tools such as FRAX may require specific
adaptations for use in the BC population.
Our results in premenopausal and postmenopausal women with
BC indicate that bone loss resulting in osteopenia and osteoporosis
are relatively common in postmenopausal women with ER
þ BC,
who are likely to receive AI therapy. Because AIs are associated
with increased risks of bone loss and fracture that persist for the
duration of treatment, active management of bone health in this
patient population is important. Using emerging international
guidelines (Hadji et al, 2008) to initiate bisphosphonate therapy in
these patients is predicted to prevent nearly half of all potential
fractures. Recently developed fracture-risk evaluation tools and
recommendations for monitoring bone health emphasise the
importance of comprehensive fracture-risk assessment and the
need for early intervention in women with BC. Future prospective
studies will be needed to assess the benefits of bisphosphonate
therapy for fracture prevention and to compare the relative
efficacy of bisphosphonates in the adjuvant setting.
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